The reiteration of a Buy rating and a $23 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Protara Therapeutics. This endorsement reaffirms the firm's confidence in the company's potential, likely encouraging both current and potential investors about TARA's future prospects.